Use of Circulating Tumor DNA for Cancer Immunotherapy
- 1 December 2019
- journal article
- review article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 25 (23) , 6909-6915
Abstract
Liquid biopsy offers a versatile, noninvasive opportunity to diagnose, characterize, and monitor disease in patients with cancer. There are particularly promising applications with which to use liquid biopsies to predict and evaluate response to immunotherapy. Circulating tumor DNA (ctDNA) can reflect the genomic state of a patient's overall disease and, thus, might identify prognostic and predictive biomarkers for immune checkpoint inhibitor therapy. ctDNA might also be a proxy for a patient's overall disease burden, which could be used for early diagnosis and monitoring treatment response. These applications can enable novel trial designs, such as enrollment of early-stage patients with a high risk for relapse, and the evaluation of response patterns unique to immunotherapies. However, barriers to the widespread adoption of ctDNA assessment remain, including the absence of standardized procedures for collecting and processing ctDNA samples and relatively limited data on clinical utility. Identifying and solving these challenges could allow ctDNA to become a powerful clinical and research tool in the era of personalized immunotherapy.Keywords
Funding Information
- No funders
This publication has 55 references indexed in Scilit:
- Capture-Based Targeted Ultradeep Sequencing in Paired Tissue and Plasma Samples Demonstrates Differential Subclonal ctDNA-Releasing Capability in Advanced Lung CancerJournal of Thoracic Oncology, 2017
- Cell-free DNA Comprises an In Vivo Nucleosome Footprint that Informs Its Tissues-Of-OriginCell, 2016
- Pseudoprogression and Immune-Related Response in Solid TumorsJournal of Clinical Oncology, 2015
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated MelanomaNew England Journal of Medicine, 2015
- Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancerAnnals of Oncology, 2015
- Detection of Circulating Tumor DNA in Early- and Late-Stage Human MalignanciesScience Translational Medicine, 2014
- Tumor Growth Rate Is an Early Indicator of Antitumor Drug Activity in Phase I Clinical TrialsClinical Cancer Research, 2014
- Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion SequencingNew England Journal of Medicine, 2012
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010
- Circulating mutant DNA to assess tumor dynamicsNature Medicine, 2008